全体要約
特発性肺線維症は、数年にわたって進行する稀な慢性疾患で、肺に瘢痕組織が形成され、呼吸困難を引き起こします。2022年の特発性肺線維症の治療市場は、地域別および市場セクター別に分析され、2023年から2029年の予測が示されています。アメリカ、中国、ヨーロッパの市場はそれぞれ成長が見込まれています。
市場は、ピルフェニドンやニンテダニブなどの製品タイプ、病院や大学などの用途に分かれています。主要企業には、ボーリンガーインゲルハイムやメルクなどが含まれ、2022年には上位2社が市場の大部分を占めました。市場の成長機会やシェアも詳細に分析されています。
関連する質問
Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma, Heilongjiang Zbd Pharmaceutical, Indaco, InterMune, Inc., Bristol Myers Squibb, SHIONOGI & CO., Ltd.
製品セグメンテーションの重要なトレンド, 主要企業の戦略分析, 地域別市場の成長機会
概要
LPI (LP Information)の最新のリサーチレポート「特発性肺線維症治療産業予測」は、過去の販売状況を考察し、2022年の世界における特発性肺線維症治療の総売上をレビューしています。2023年から2029年にかけての予測された特発性肺線維症治療売上について、地域や市場セクターごとの包括的な分析を提供。特発性肺線維症治療の売上は地域、マーケットセクター、サブセクターごとに分解されており、世界の特発性肺線維症治療業界の詳細な分析をUSドル百万単位で提供。
このインサイトレポートは、世界の特発性肺線維症治療の状況に関する包括的な分析を提供し、製品のセグメンテーション、企業の形成、収益、市場シェア、最新の開発、およびM&A活動に関連する重要なトレンドを強調しています。このレポートはまた、特発性肺線維症治療ポートフォリオと能力、市場参入戦略、市場ポジション、地理的なフットプリントに焦点を当てて、主要なグローバル企業の戦略を分析し、加速するグローバルな特発性肺線維症治療市場におけるこれらの企業の独自の立ち位置をよりよく理解することを目的としています。
このインサイトレポートでは、特発性肺線維症治療の世界的な展望を形成する主要な市場トレンド、ドライバー、および影響因子を評価し、タイプ、用途、地域、市場規模別に予測を分解して、新たな機会のポケットを明らかにします。数百のボトムアップ質的および量的市場インプットに基づく透明な方法論を用いたこの研究は、特発性肺線維症治療の現状と将来の軌道に関する非常に微妙な見解を提供します。
世界の特発性肺線維症疾患治療市場の規模は、2022年のXX米ドルから2029年のXX米ドルへの成長が予測されています。2023年から2029年にかけて、CAGRはXX%の成長が期待されています。
アメリカの特発性肺線維症治療市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると予測されており、2023年から2029年の間にXX%のCAGRを記録する見込みです。
中国における特発性肺線維症治療市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると見込まれており、2023年から2029年までの間にXX%のCAGRを記録する見込みです。
特発性肺線維症治療のヨーロッパ市場は、2022年のXX米ドルから2029年までにXX米ドルに増加すると見込まれており、2023年から2029年までの年平均成長率（CAGR）はXX%です。
グローバルな重要な特発性肺線維症治療のプレイヤーには、ベーリンガーインゲルハイム、メルク・アンド・カンパニー、アークバイオ、ゼルジェン、ブレードセラピューティクス、レジェンドセラピューティクス（ケイマン）社、インシリコメディスン、ヴィコアファーマ、ハイロンジアンZbd製薬などが含まれます。2022年の収益に関して、世界の2大企業はほぼXX%のシェアを占めていました。
このレポートは、特発性肺線維症治療市場の製品タイプ、用途、主要プレーヤー、主要地域および国別の包括的な概要、市場シェア、成長機会を提示します。
市場セグメンテーション
タイプ別のセグメンテーション
ピルフェニドン
ニンテダニブ
その他
アプリケーション別セグメンテーション
病院
大学院
その他
この報告書は地域別に市場を分割しています：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下にプロフィールが記載されている企業は、主要な専門家から得られた情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透度を分析した結果に基づいて選定されました。
バイエルインゲルハイム
メルク社
アークバイオ
ゼルゲン
ブレイドセラピューティクス
レジェンドセラピューティクス（ケイマン）株式会社
インシリコメディスン
ヴィコア・ファーマ
黒竜江Zbd製薬
インダコ
インターミュン・インク
ブリストル・マイヤーズ スクイブ
塩野義製薬株式会社
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの特発性肺線維症の治療市場規模、（2018年～2029年）
2.1.2 特発性肺線維症の治療市場規模、CAGR（地域別）（2018年 vs 2022年 vs 2029年）
2.2 特発性肺線維症の治療セグメント、タイプ別
2.2.1 ピルフェニドン
2.2.2 ニンテダニブ
2.2.3 その他
2.3 特発性肺線維症の治療市場規模：タイプ別
2.3.1 特発性肺線維症の治療市場規模、CAGR（タイプ別）（2018年 vs 2022年 vs 2029年）
2.3.2 グローバルの特発性肺線維症の治療市場規模、市場シェア（タイプ別）（2018年～2023年）
2.4 特発性肺線維症の治療セグメント、用途別
2.4.1 病院
2.4.2 大学院
2.4.3 その他
2.5 特発性肺線維症の治療市場規模：用途別
2.5.1 特発性肺線維症の治療市場規模、CAGR（用途別）（2018年 vs 2022年 vs 2029年）
2.5.2 グローバルの特発性肺線維症の治療市場規模、市場シェア（用途別）（2018年～2023年）
3 特発性肺線維症の治療市場規模：プレイヤー別
3.1 特発性肺線維症の治療市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける特発性肺線維症の治療市場の収益規模、プレイヤー別（2018年～2023年）
3.1.2 グローバルにおける特発性肺線維症の治療市場の収益シェア、プレイヤー別（2018年～2023年）
3.2 グローバルの特発性肺線維症の治療市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2021年～2023年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 特発性肺線維症の治療、地域別
4.1 特発性肺線維症の治療市場規模（地域別）（2018年～2023年）
4.2 アメリカズにおける特発性肺線維症の治療市場規模成長（2018年〜2023年）
4.3 APACにおける特発性肺線維症の治療市場規模成長（2018年〜2023年）
4.4 ヨーロッパにおける特発性肺線維症の治療市場規模成長（2018年〜2023年）
4.5 中東・アフリカにおける特発性肺線維症の治療市場規模成長（2018年〜2023年）
5 アメリカズ
5.1 アメリカズにおける特発性肺線維症の治療市場規模、国別（2018年〜2023年）
5.2 アメリカズにおける特発性肺線維症の治療市場規模、タイプ別（2018年〜2023年）
5.3 アメリカズにおける特発性肺線維症の治療市場規模、用途別（2018年〜2023年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける特発性肺線維症の治療市場規模、地域別（2018年〜2023年）
6.2 APACにおける特発性肺線維症の治療市場規模、タイプ別（2018年〜2023年）
6.3 APACにおける特発性肺線維症の治療市場規模、用途別（2018年〜2023年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの特発性肺線維症の治療 国別（2018年～2023年）
7.2 ヨーロッパにおける特発性肺線維症の治療市場規模、タイプ別（2018年〜2023年）
7.3 ヨーロッパにおける特発性肺線維症の治療市場規模、用途別（2018年〜2023年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの特発性肺線維症の治療 地域別（2018年～2023年）
8.2 中東・アフリカにおける特発性肺線維症の治療市場規模、タイプ別（2018年〜2023年）
8.3 中東・アフリカにおける特発性肺線維症の治療市場規模、用途別（2018年〜2023年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの特発性肺線維症の治療市場、市場予測
10.1 グローバルの特発性肺線維症の治療、市場予測（地域別）（2024年～2029年）
10.1.1 グローバルの特発性肺線維症の治療、市場予測（地域別）（2024年～2029年）
10.1.2 アメリカズの特発性肺線維症の治療、市場予測
10.1.3 APACの特発性肺線維症の治療、市場予測
10.1.4 ヨーロッパの特発性肺線維症の治療、市場予測
10.1.5 中東・アフリカの特発性肺線維症の治療、市場予測
10.2 アメリカズの特発性肺線維症の治療、市場予測（国別）（2024年～2029年）
10.3 APACの特発性肺線維症の治療、市場予測（地域別）（2024年～2029年）
10.4 ヨーロッパの特発性肺線維症の治療、市場予測（国別）（2024年～2029年）
10.5 中東・アフリカの特発性肺線維症の治療、市場予測（地域別）（2024年～2029年）
10.6 グローバルの特発性肺線維症の治療、市場予測（タイプ別）（2024年～2029年）
10.7 グローバルの特発性肺線維症の治療、市場予測（用途別）（2024年～2029年）
11 キープレイヤー分析
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim：企業情報
11.1.2 Boehringer Ingelheim：特発性肺線維症の治療分野の提供製品
11.1.3 Boehringer Ingelheim：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.1.4 Boehringer Ingelheim：主要事業概要
11.1.5 Boehringer Ingelheim：直近の展開
11.2 Merck and Co\., Inc
11.3 ArkBio
11.3.1 ArkBio：企業情報
11.3.2 ArkBio：特発性肺線維症の治療分野の提供製品
11.3.3 ArkBio：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.3.4 ArkBio：主要事業概要
11.3.5 ArkBio：直近の展開
11.4 Zelgen
11.4.1 Zelgen：企業情報
11.4.2 Zelgen：特発性肺線維症の治療分野の提供製品
11.4.3 Zelgen：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.4.4 Zelgen：主要事業概要
11.4.5 Zelgen：直近の展開
11.5 Blade Therapeutics
11.5.1 Blade Therapeutics：企業情報
11.5.2 Blade Therapeutics：特発性肺線維症の治療分野の提供製品
11.5.3 Blade Therapeutics：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.5.4 Blade Therapeutics：主要事業概要
11.5.5 Blade Therapeutics：直近の展開
11.6 Regend Therapeutics \(Cayman\) Ltd
11.7 Insilico Medicine
11.7.1 Insilico Medicine：企業情報
11.7.2 Insilico Medicine：特発性肺線維症の治療分野の提供製品
11.7.3 Insilico Medicine：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.7.4 Insilico Medicine：主要事業概要
11.7.5 Insilico Medicine：直近の展開
11.8 Vicore Pharma
11.8.1 Vicore Pharma：企業情報
11.8.2 Vicore Pharma：特発性肺線維症の治療分野の提供製品
11.8.3 Vicore Pharma：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.8.4 Vicore Pharma：主要事業概要
11.8.5 Vicore Pharma：直近の展開
11.9 Heilongjiang Zbd Pharmaceutical
11.9.1 Heilongjiang Zbd Pharmaceutical：企業情報
11.9.2 Heilongjiang Zbd Pharmaceutical：特発性肺線維症の治療分野の提供製品
11.9.3 Heilongjiang Zbd Pharmaceutical：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.9.4 Heilongjiang Zbd Pharmaceutical：主要事業概要
11.9.5 Heilongjiang Zbd Pharmaceutical：直近の展開
11.10 Indaco
11.10.1 Indaco：企業情報
11.10.2 Indaco：特発性肺線維症の治療分野の提供製品
11.10.3 Indaco：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.10.4 Indaco：主要事業概要
11.10.5 Indaco：直近の展開
11.11 InterMune, Inc
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb：企業情報
11.12.2 Bristol Myers Squibb：特発性肺線維症の治療分野の提供製品
11.12.3 Bristol Myers Squibb：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2018年～2023年）
11.12.4 Bristol Myers Squibb：主要事業概要
11.12.5 Bristol Myers Squibb：直近の展開
11.13 SHIONOGI & CO\., Ltd
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Disease Treatment Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis Disease Treatment sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis Disease Treatment.
The global Idiopathic Pulmonary Fibrosis Disease Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Idiopathic Pulmonary Fibrosis Disease Treatment players cover Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma and Heilongjiang Zbd Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis Disease Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pirfenidone
Nintedanib
Other
Segmentation by application
Hospital
Graduate School
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2029
2.1.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Type
2.2.1 Pirfenidone
2.2.2 Nintedanib
2.2.3 Other
2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type
2.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023)
2.4 Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Application
2.4.1 Hospital
2.4.2 Graduate School
2.4.3 Others
2.5 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application
2.5.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023)
3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Player
3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Players
3.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Players (2018-2023)
3.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Idiopathic Pulmonary Fibrosis Disease Treatment by Regions
4.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Regions (2018-2023)
4.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
5 Americas
5.1 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2018-2023)
5.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
5.3 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2018-2023)
6.2 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
6.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment by Country (2018-2023)
7.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
7.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment by Region (2018-2023)
8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Regions (2024-2029)
10.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Regions (2024-2029)
10.1.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Country (2024-2029)
10.2.1 United States Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.2 Canada Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.3 Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.4 Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Region (2024-2029)
10.3.1 China Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.2 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.3 Korea Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.4 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.5 India Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.6 Australia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Country (2024-2029)
10.4.1 Germany Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.2 France Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.3 UK Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.4 Italy Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.5 Russia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Region (2024-2029)
10.5.1 Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.2 South Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.3 Israel Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.4 Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.5 GCC Countries Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.6 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Type (2024-2029)
10.7 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Information
11.1.2 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Boehringer Ingelheim Main Business Overview
11.1.5 Boehringer Ingelheim Latest Developments
11.2 Merck and Co., Inc.
11.2.1 Merck and Co., Inc. Company Information
11.2.2 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.2.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck and Co., Inc. Main Business Overview
11.2.5 Merck and Co., Inc. Latest Developments
11.3 ArkBio
11.3.1 ArkBio Company Information
11.3.2 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.3.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 ArkBio Main Business Overview
11.3.5 ArkBio Latest Developments
11.4 Zelgen
11.4.1 Zelgen Company Information
11.4.2 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.4.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Zelgen Main Business Overview
11.4.5 Zelgen Latest Developments
11.5 Blade Therapeutics
11.5.1 Blade Therapeutics Company Information
11.5.2 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.5.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Blade Therapeutics Main Business Overview
11.5.5 Blade Therapeutics Latest Developments
11.6 Regend Therapeutics (Cayman) Ltd.
11.6.1 Regend Therapeutics (Cayman) Ltd. Company Information
11.6.2 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.6.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Regend Therapeutics (Cayman) Ltd. Main Business Overview
11.6.5 Regend Therapeutics (Cayman) Ltd. Latest Developments
11.7 Insilico Medicine
11.7.1 Insilico Medicine Company Information
11.7.2 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.7.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Insilico Medicine Main Business Overview
11.7.5 Insilico Medicine Latest Developments
11.8 Vicore Pharma
11.8.1 Vicore Pharma Company Information
11.8.2 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.8.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Vicore Pharma Main Business Overview
11.8.5 Vicore Pharma Latest Developments
11.9 Heilongjiang Zbd Pharmaceutical
11.9.1 Heilongjiang Zbd Pharmaceutical Company Information
11.9.2 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.9.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Heilongjiang Zbd Pharmaceutical Main Business Overview
11.9.5 Heilongjiang Zbd Pharmaceutical Latest Developments
11.10 Indaco
11.10.1 Indaco Company Information
11.10.2 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.10.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Indaco Main Business Overview
11.10.5 Indaco Latest Developments
11.11 InterMune, Inc.
11.11.1 InterMune, Inc. Company Information
11.11.2 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.11.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 InterMune, Inc. Main Business Overview
11.11.5 InterMune, Inc. Latest Developments
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb Company Information
11.12.2 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.12.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Bristol Myers Squibb Main Business Overview
11.12.5 Bristol Myers Squibb Latest Developments
11.13 SHIONOGI & CO., Ltd.
11.13.1 SHIONOGI & CO., Ltd. Company Information
11.13.2 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.13.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 SHIONOGI & CO., Ltd. Main Business Overview
11.13.5 SHIONOGI & CO., Ltd. Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions) Table 2. Major Players of Pirfenidone Table 3. Major Players of Nintedanib Table 4. Major Players of Other Table 5. Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions) Table 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023) & ($ Millions) Table 7. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Table 8. Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions) Table 9. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023) & ($ Millions) Table 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Table 11. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Players (2018-2023) & ($ Millions) Table 12. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Player (2018-2023) Table 13. Idiopathic Pulmonary Fibrosis Disease Treatment Key Players Head office and Products Offered Table 14. Idiopathic Pulmonary Fibrosis Disease Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) Table 15. New Products and Potential Entrants Table 16. Mergers & Acquisitions, Expansion Table 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Regions 2018-2023 & ($ Millions) Table 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Regions (2018-2023) Table 19. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Country/Region (2018-2023) & ($ millions) Table 20. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Country/Region (2018-2023) Table 21. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2018-2023) & ($ Millions) Table 22. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Country (2018-2023) Table 23. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023) & ($ Millions) Table 24. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Table 25. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023) & ($ Millions) Table 26. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Table 27. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2018-2023) & ($ Millions) Table 28. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Region (2018-2023) Table 29. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023) & ($ Millions) Table 30. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Table 31. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023) & ($ Millions) Table 32. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Table 33. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2018-2023) & ($ Millions) Table 34. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Country (2018-2023) Table 35. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023) & ($ Millions) Table 36. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Table 37. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023) & ($ Millions) Table 38. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Table 39. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2018-2023) & ($ Millions) Table 40. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Region (2018-2023) Table 41. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023) & ($ Millions) Table 42. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Table 43. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023) & ($ Millions) Table 44. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Table 45. Key Market Drivers & Growth Opportunities of Idiopathic Pulmonary Fibrosis Disease Treatment Table 46. Key Market Challenges & Risks of Idiopathic Pulmonary Fibrosis Disease Treatment Table 47. Key Industry Trends of Idiopathic Pulmonary Fibrosis Disease Treatment Table 48. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Regions (2024-2029) & ($ Millions) Table 49. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share Forecast by Regions (2024-2029) Table 50. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Type (2024-2029) & ($ Millions) Table 51. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Application (2024-2029) & ($ Millions) Table 52. Boehringer Ingelheim Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 53. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 54. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 55. Boehringer Ingelheim Main Business Table 56. Boehringer Ingelheim Latest Developments Table 57. Merck and Co., Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 58. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 59. Merck and Co., Inc. Main Business Table 60. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 61. Merck and Co., Inc. Latest Developments Table 62. ArkBio Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 63. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 64. ArkBio Main Business Table 65. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 66. ArkBio Latest Developments Table 67. Zelgen Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 68. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 69. Zelgen Main Business Table 70. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 71. Zelgen Latest Developments Table 72. Blade Therapeutics Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 73. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 74. Blade Therapeutics Main Business Table 75. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 76. Blade Therapeutics Latest Developments Table 77. Regend Therapeutics (Cayman) Ltd. Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 78. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 79. Regend Therapeutics (Cayman) Ltd. Main Business Table 80. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 81. Regend Therapeutics (Cayman) Ltd. Latest Developments Table 82. Insilico Medicine Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 83. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 84. Insilico Medicine Main Business Table 85. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 86. Insilico Medicine Latest Developments Table 87. Vicore Pharma Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 88. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 89. Vicore Pharma Main Business Table 90. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 91. Vicore Pharma Latest Developments Table 92. Heilongjiang Zbd Pharmaceutical Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 93. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 94. Heilongjiang Zbd Pharmaceutical Main Business Table 95. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 96. Heilongjiang Zbd Pharmaceutical Latest Developments Table 97. Indaco Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 98. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 99. Indaco Main Business Table 100. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 101. Indaco Latest Developments Table 102. InterMune, Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 103. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 104. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 105. InterMune, Inc. Main Business Table 106. InterMune, Inc. Latest Developments Table 107. Bristol Myers Squibb Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 108. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 109. Bristol Myers Squibb Main Business Table 110. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 111. Bristol Myers Squibb Latest Developments Table 112. SHIONOGI & CO., Ltd. Details, Company Type, Idiopathic Pulmonary Fibrosis Disease Treatment Area Served and Its Competitors Table 113. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered Table 114. SHIONOGI & CO., Ltd. Main Business Table 115. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 116. SHIONOGI & CO., Ltd. Latest Developments List of Figures Figure 1. Idiopathic Pulmonary Fibrosis Disease Treatment Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate 2018-2029 ($ Millions) Figure 6. Idiopathic Pulmonary Fibrosis Disease Treatment Sales by Geographic Region (2018, 2022 & 2029) & ($ millions) Figure 7. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share by Country/Region (2022) Figure 8. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share by Country/Region (2018, 2022 & 2029) Figure 9. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type in 2022 Figure 10. Idiopathic Pulmonary Fibrosis Disease Treatment in Hospital Figure 11. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market: Hospital (2018-2023) & ($ Millions) Figure 12. Idiopathic Pulmonary Fibrosis Disease Treatment in Graduate School Figure 13. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market: Graduate School (2018-2023) & ($ Millions) Figure 14. Idiopathic Pulmonary Fibrosis Disease Treatment in Others Figure 15. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market: Others (2018-2023) & ($ Millions) Figure 16. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application in 2022 Figure 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Player in 2022 Figure 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Regions (2018-2023) Figure 19. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2023 ($ Millions) Figure 20. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2023 ($ Millions) Figure 21. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2023 ($ Millions) Figure 22. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2023 ($ Millions) Figure 23. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Value Market Share by Country in 2022 Figure 24. United States Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 25. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 26. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 27. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 28. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Region in 2022 Figure 29. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type in 2022 Figure 30. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application in 2022 Figure 31. China Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 32. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 33. Korea Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 34. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 35. India Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 36. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 37. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Country in 2022 Figure 38. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Figure 39. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Figure 40. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 41. France Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 42. UK Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 43. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 44. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Region (2018-2023) Figure 46. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023) Figure 47. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023) Figure 48. Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 49. South Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 50. Israel Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 51. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 52. GCC Country Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth 2018-2023 ($ Millions) Figure 53. Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 54. APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 55. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 56. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 57. United States Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 58. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 59. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 60. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 61. China Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 62. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 63. Korea Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 64. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 65. India Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 66. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 67. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 68. France Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 69. UK Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 70. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 71. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 72. Spain Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 73. Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 74. South Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 75. Israel Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 76. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 77. GCC Countries Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2024-2029 ($ Millions) Figure 78. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share Forecast by Type (2024-2029) Figure 79. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share Forecast by Application (2024-2029)
